291 related articles for article (PubMed ID: 10449550)
21. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review.
Ghika J; Villemure JG; Fankhauser H; Favre J; Assal G; Ghika-Schmid F
J Neurosurg; 1998 Nov; 89(5):713-8. PubMed ID: 9817406
[TBL] [Abstract][Full Text] [Related]
22. Parkinson's disease: progression and mortality in the L-DOPA era.
Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
[No Abstract] [Full Text] [Related]
23. Parkinson's disease: progression and mortality.
Hoehn MM
Adv Neurol; 1987; 45():457-61. PubMed ID: 3825726
[TBL] [Abstract][Full Text] [Related]
24. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Hauser RA; Holford NH
Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
[TBL] [Abstract][Full Text] [Related]
25. Parkinsonism treated with levodopa: progression and mortality.
Maier Hoehn MM
J Neural Transm Suppl; 1983; 19():253-64. PubMed ID: 6583311
[TBL] [Abstract][Full Text] [Related]
26. Parkinson's disease patients first treated at age 75 years or older: a comparative study.
Peretz C; Chillag-Talmor O; Linn S; Gurevich T; El-Ad B; Silverman B; Friedman N; Giladi N
Parkinsonism Relat Disord; 2014 Jan; 20(1):69-74. PubMed ID: 24183677
[TBL] [Abstract][Full Text] [Related]
27. [Hospital Mortality in Parkinson's Disease: Retrospective Analysis in a Portuguese Tertiary Centre].
Martins J; Rua A; Vila Chã N
Acta Med Port; 2016 May; 29(5):315-8. PubMed ID: 27649015
[TBL] [Abstract][Full Text] [Related]
28. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
29. Bromocriptine therapy in early-stage Parkinson's disease.
Fukuyama H; Kawamura J; Akiguchi I; Kimura J; Imai T
Eur Neurol; 1996; 36(3):164-70. PubMed ID: 8738948
[TBL] [Abstract][Full Text] [Related]
30. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
31. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Libman I; Gawel MJ; Riopelle RJ; Bouchard S
Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
[TBL] [Abstract][Full Text] [Related]
32. Mortality and causes of death in idiopathic Parkinson's disease: results from the Aberdeen whole population study.
Ebmeier KP; Calder SA; Crawford JR; Stewart L; Besson JA; Mutch WJ
Scott Med J; 1990 Dec; 35(6):173-5. PubMed ID: 2077649
[TBL] [Abstract][Full Text] [Related]
33. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
34. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
Lhommée E; Wojtecki L; Czernecki V; Witt K; Maier F; Tonder L; Timmermann L; Hälbig TD; Pineau F; Durif F; Witjas T; Pinsker M; Mehdorn M; Sixel-Döring F; Kupsch A; Krüger R; Elben S; Chabardès S; Thobois S; Brefel-Courbon C; Ory-Magne F; Regis JM; Maltête D; Sauvaget A; Rau J; Schnitzler A; Schüpbach M; Schade-Brittinger C; Deuschl G; Houeto JL; Krack P;
Lancet Neurol; 2018 Mar; 17(3):223-231. PubMed ID: 29452685
[TBL] [Abstract][Full Text] [Related]
35. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
36. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
Przuntek H; Welzel D; Gerlach M; Blümner E; Danielczyk W; Kaiser HJ; Kraus PH; Letzel H; Riederer P; Uberla K
J Neural Transm (Vienna); 1996; 103(6):699-715. PubMed ID: 8836932
[TBL] [Abstract][Full Text] [Related]
37. [A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].
Shimo Y; Takanashi M; Ohta S; Terashima K; Mori H; Shirai T; Miwa H; Mizuno Y
No To Shinkei; 2001 May; 53(5):495-505. PubMed ID: 11428377
[TBL] [Abstract][Full Text] [Related]
38. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).
Reid WG; Hely MA; Morris JG; Loy C; Halliday GM
J Neurol Neurosurg Psychiatry; 2011 Sep; 82(9):1033-7. PubMed ID: 21335570
[TBL] [Abstract][Full Text] [Related]
39. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
[TBL] [Abstract][Full Text] [Related]
40. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
Montastruc JL; Rascol O; Senard JM; Rascol A
J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
